As reported earlier by us, the strongest evidence is with regard to LGG. In hospitalized children, the use of LGG reduced the overall incidence of healthcare-associated diarrhea, including rotavirus gastroenteritis. Evidence limited to one RCT suggests the efficacy of B. bifidum & Str. thermophilus. Other studied probiotics, i.e., L. reuteri DSM 17938 and L. delbrueckii H2B20, were ineffective. However, again, the evidence is limited to single trials only. This systematic review adds to previously published data, as it allowed identification of all probiotics whose efficacy for preventing nosocomial infections has been assessed. Thus, in addition to LGG, the efficacy of which was reported by us previously

[8], we included data on other microorganisms. This selleck inhibitor is valuable as, worldwide, the availability of probiotic products differs. Thus, our systematic review may have practical implications. It allows one to answer the question of which of the locally Enzalutamide molecular weight available probiotics, if any, are effective. In contrast to the authors of many other meta-analyses, we abstained from pooling data on different probiotics. This is because it has been repeatedly questioned, also by our group, whether it is appropriate to pool data on different probiotic microorganisms [18]. We

strongly support the view that pooling data from different genera, species, and strains may result in misleading conclusions. Efforts were made to identify all published evidence. For example, we searched several databases with no language restrictions. However, the possibility of missing data cannot be excluded. Publication bias remains

a possible source of important bias. To our knowledge, except for our review on the efficacy of LGG [8] there are no other systematic reviews that have focused exclusively on the effectiveness of probiotics for the prevention of healthcare-associated diarrhea in hospitalized children. In the absence of other effective measures, evidence supporting the use of LGG to reduce the risk of healthcare-associated diarrhea is encouraging. With regard to the other probiotics studied, data, whether positive or negative, are too limited to draw reliable conclusions. In the future, after a more universal introduction of rotavirus vaccination, the burden of nosocomial diarrhea and responsible Sclareol pathogens may change as recently documented. In some countries, such as the US, norovirus has emerged as the leading cause of medically attended gastroenteritis [19]. If so, the efficacy of probiotics for preventing nosocomial diarrhea needs to be reassessed. Further studies are also recommended to address the cost-effectiveness of using LGG, or other probiotics with documented efficacy, for the prevention of healthcare-associated diarrhea. Although none of the included studies reported adverse events, standardized and clear adverse event reporting is essential for future trials.